Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization

Journal of Immunological Methods

Volumn 220, Issue 1-2, 1998, Pages 93-103

  Durrani, Zarmina ^a   McInerney, Tracey L ^a   McLain, Lesley ^a   Jones, Tim ^b   Bellaby, Trevor ^b   Brennan, Frank R ^b   Dimmock, Nigel J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b Axis Genetics plc   (United Kingdom)

Author keywords

Antibody; Cowpea mosaic virus; Gp41; HIV 1; IgA; Intranasal vaccine; Plant virus chimera; T(H)1 response; Vaccine

Indexed keywords

CHOLERA TOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; VIRUS ANTIBODY;

ANTIBODY DETECTION; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; MUCOSAL IMMUNITY; NONHUMAN; PLANT VIRUS; PRIORITY JOURNAL; VIRUS TRANSMISSION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; COMOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; GENETIC VECTORS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTESTINAL MUCOSA; MICE; MICE, INBRED C3H; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC;

COWPEA MOSAIC VIRUS; HIV 1; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031792544     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(98)00145-8     Document Type: Article

References (53)

1. Abraham Intranasal immunization with bacterial polysaccharide containing liposomes enhances antigen-specific pulmonary secretory antibody response. Vaccine. 10:1992;461.
2. Adams S.E., Dawson K.M., Gull K., Kingsman S.M., Kingsman A.J. The expression of hybrid HIV-Ty virus-like particles in yeast. Nature. 329:1987;68.
3. Almeida A.J., Alpar H.O. Nasal delivery of vaccines. J. Drug Targeting. 3:1996;455.
4. Almond N., Kent K., Cranage M., Rud E., Clarke B., Stott E.J. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet. 345:1995;1342.
5. Al-Sabbagh A., Nelson P.A., Akselband Y., Sobel R.A., Weiner H.L. Antigen-driven peripheral immune tolerance: suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen. Cell. Immunol. 171:1996;111.
6. Alving C.R. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiol. 187:1993;430.
7. H2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. AIDS. 8:1994;757.
8. Bukawa H., Sekigawa K.-I., Hamajima K., Fukushima J., Yamada Y., Kiyono H., Okuda K. Neutralization of HIV by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nat. Med. 1:1995;681.
9. Buratti E., Tisminetzky S.G., Scodeller E.S., Baralle F.E. Conformational display of two neutralizing epitopes of HIV-1 gp41 in the flock house virus capsid protein. J. Immunol. Meth. 197:1996;7.
10. Challacombe S., Rahman D., O'Hagan D.T. Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine. 15:1997;169.
11. H2 switch is a critical step in the etiology of HIV infection. Immunol. Today. 14:1993;107.
12. Clerici M., Sison A.V., Berzofsky J.A., Rakusan T.A., Brandt C.D., Elluarie M., Villa M., Colie C., Venzon D.J., Sever J.L., Shearer G.M. Cellular immune factors associated with mother-to-infant transmission of HIV. AIDS. 7:1993;1427.
13. Clerici M., Levin J.M., Kessler H.A., Hams A., Berzofsky J.A., Landay A.L., Shearer G.M. HIV-specific T-helper activity in seronegative health-care workers exposed to contaminated blood. J. Am. Med. Assoc. 271:1994;42.
14. H2 hypothesis of HIV infection: new insights. Immunol. Today. 15:1994;575.
15. Coffman R.L., Varkila K., Scott P., Chatelain R. Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo. Immunol. Rev. 123:1991;189.
16. Collins F.M. Vaccines and cell-mediated immunity. Bact. Rev. 38:1974;371.
17. Dalsgaard K., Uttenthal A., Jones T.D., Xu F., Merryweather A., Hamilton W.D.O.H., Langeveld J.P.M., Boshuizen R.S., Kamstrup S., Lomonossoff G.P., Porta C., Vela C., Casal J.I., Meloen R.H., Rodgers P.B. Plant-derived vaccine protects target animals against a viral disease. Nat. Biotech. 15:1997;248.
18. Daniel M.D., Kirchhoff F., Czajak S.C., Sehgal P.K., Desrosiers R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 258:1992;1938.
19. Dick A.D., Cheng Y.F., Liversidge J., Forrester J.V. Intranasal administration of retinal antigens suppresses retinal antigen-induced experimental autoimmune uveoretinitis. Immunology. 82:1994;625.
20. Dickinson, B.L., Clements, J.D., 1996. Use of Escherichia coli heat-labile toxin as an oral adjuvant. In: Kiyono, H., Ogra, P.L., McGhee, J.R. (Eds.), Mucosal Vaccines. Academic Press, San Diego, CA, p. 73.
21. Elson, C.O., Dertzbaugh, M.T., 1994. Mucosal adjuvants. In: Ogra, P.L., Mestecky, J., Lamm, M.E., Strober, W., McGhee, J.R., Bienenstock, J. (Eds.), Handbook of Mucosal Immunity. Academic Press, New York, p. 391.
22. Feng N., Burns J.W., Bracy L., Greenberg H.B. Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus. J. Virol. 68:1994;7766.
23. Gupta R.K., Siber G.R. Adjuvants for human vaccines: current status, problems, and future prospects. Vaccine. 13:1995;1263.
24. Hirabayashi Y., Kurata H., Funato H., Nagamine T., Aizawa C., Tamura S.-I., Shimada K., Kurata T. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine. 8:1990;243.
25. Holt P.G., McMenamin C. Defence against allergic sensitisation in the healthy lung: the role of inhalational tolerance. Clin. Exp. Allergy. 19:1989;255.
26. Hone D.M., Tackett C.O., Harris A.M., Kay B., Losonsky G., Levine M.M. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J. Clin. Invest. 90:1992;412.
27. Hsu S.-C., Schadeck E.B., Delmas A., Shaw M., Steward M.W. Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMS and induction of CTL reponses following intranasal immunization. Vaccine. 14:1996;1159.
28. Kumar V., Sercarz E. Genetic vaccination: the advantages of going naked. Nat. Med. 2:1996;857.
29. Lehner T., Panagiotidi C., Bergmeier L.A., Ping T., Brookes R., Adams S.E. A comparison of the immune responses following oral, vaginal, or rectal route of immunization with SIV antigens in nonhuman primates. Vaccine Res. 1:1992;319.
30. Lehner T., Bergmeier L.A., Panagiotidi C., Tao L., Brookes R., Klavinskis L.S., Walker P., Walker J., Ward R.G., Hussain L., Gearing A.J.H., Adams S.E. Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein. Science. 258:1992;136.
31. Maloy K.J., Donachie A.M., O'Hagan D.T., Mowat A.M. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology. 81:1994;661.
32. Marx P.A., Compans R.W., Gettie A., Staas J.K., Gilley R.M., Mulligan M.J., Yamshchikov G.V., Chen D., Eldridge J.H. Protection against vaginal SIV transmission with microencapsulated vaccine. Science. 260:1993;1323.
33. McLain L., Porta C., Lomonossoff G.P., Durrani Z., Dimmock N.J. Human immunodeficiency virus type 1 neutralizing antibodies raised to a gp41 peptide expressed on the surface of a plant virus. AIDS Res. Hum. Retroviruses. 11:1995;327.
34. McLain L., Durrani Z., Wisniewski L.A., Porta C., Lomonossoff G.P., Dimmock N.J. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22-mer amino acid peptide expressed on the surface of a plant virus. Vaccine. 14:1996;799.
35. McLain, L., Durrani, Z., Wisniewski, L.A., Porta, C., Lomonossoff, G.P., Dimmock, N.J., 1996b. A plant virus-HIV-1 chimera stimulates antibody that neutralizes HIV-1. In: Brown, F., Burton, D.R., Collier, J., Mekalonos, J., Norrby, E. (Eds.), Vaccine 96. Cold Spring Harbor Laboratory, NY, p. 311.
36. Minor P.D. Antigenic structure of picornaviruses. Curr. Topics Microbiol. Immunol. 161:1990;121.
37. H2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann. Rev. Immunol. 7:1989;145.
38. Muller C.P., Beauverger P., Schneider F., Jung G., Brons N.H.C. Cholera toxin B stimulates systemic neutralizing antibodies after intranasal co-immunization with measles virus. J. Gen. Virol. 76:1995;1371.
39. Muster T., Ferko B., Klima A., Purtscher M., Trkola A., Schulz P., Grassauer A., Engelhardt O.G., Garcia-Sastre A., Palese P., Katinger H. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J. Virol. 69:1995;6678.
40. Navikas V., Link J., Wharen B., Persson C., link H. Increased levels of interferon-gamma, IL-4 and transforming growth-factor-beta messenger-RNA expressing blood mononuclear-cells in human HIV-infection. J. Clin. Exp. Immunol. 96:1994;59.
41. Navikas V., Link J., Persson C., Olsson T., Hojeberg B., Ljungokahl A., Link H., Wharen B. Increased messenger-RNA expression of IL-6, IL-10, TNF-alpha and perforin in blood mononuclear-cells in human HIV-infection J. Acq. Imm. Def. Syn. Hum. Retrovirol. 9:1995;484.
42. O'Hagan D.T., Ott G.S., Van Nest G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Molec. Med. Today. 69:1997.
43. O'Neil C.M., Crawford S.E., Estes M.K., Conner M.E. Rotavirus-like particles administered mucosally induce protective immunity. J. Virol. 71:1997;8707.
44. Partidos C.D., Vohra P., Steward M.W. Induction of measles-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides. Immunology. 87:1996;179.
45. Staats H.F., Nichols W.G., Palker T.J. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J. Immunol. 157:1996;462.
46. Tomasi T.B. Jr. Oral tolerance. Transplantation. 29:1980;353.
47. Usha R., Rohll J., Spall V.E., Shanks M., Maule A.J., Johnson J.E., Lomonossoff G.P. Expression of an animal virus antigenic site on the surface of a plant virus particle. Virology. 197:1993;366.
48. VanCott J.L., Staats H.F., Pascual D.W., Roberts M., Chatfield S.N., Yamamoto M., Coste M., Carter P.B., Kiyono H., McGhee J.R. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella. J. Immunol. 156:1996;1505.
49. Vella C., Ferguson M., Dunn G., Meloen R., Langedijk H., Evans D., Minor P.D. Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera. J. Gen. Virol. 74:1993;2603.
50. Vlacha V., Forman E.N., Miron D., Peter G. Recurrent thrombocytopenic purpura after repeated measles/mumps/rubella vaccination. Pediatrics. 97:1996;738.
51. Walker R.I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine. 12:1994;387.
52. Wu H., Russell M.W. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect. Immun. 61:1993;314.
53. Yamamoto S., Takeda Y., Yamamoto M., Kurazono H., Imaoka K., Yamamoto M., Fujihashi K., Noda M., Kiyono H., McGhee J.R. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrhoeagenicity but retain adjuvanticity. J. Exp. Med. 185:1997;1203.